Literature DB >> 9624577

Cells and molecules involved in the development of sarcoid granuloma.

C Agostini1, U Basso, G Semenzato.   

Abstract

Although the etiology of sarcoidosis is still unknown, characteristic morphologic aspects and immunohistological patterns of sarcoid granulomatous lesions suggest that they are the consequence of an exaggerated immunological response against an undefined antigen which persists at different sites of disease involvement. This article reviews the newly emerging hypothesis regarding the molecular bases which drive the development of sarcoid granulomas. The accumulation of Th1 cells represents the pivotal step along the series of events that lead to the formation of granuloma; furthermore, a set of biological mediators of the immune response define immune regulatory networks that may contribute to tissue damage. It is also thought that shifts of the Th1/Th2 networks and alterations in the complex networks between immunocompetent cells and mesenchymal cells may set the stage for the remodeling of tissues surrounding granulomatous lesions.

Entities:  

Mesh:

Year:  1998        PMID: 9624577     DOI: 10.1023/a:1020526904867

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  54 in total

1.  Increased numbers of T lymphocytes with gamma delta-positive antigen receptors in a subgroup of individuals with pulmonary sarcoidosis.

Authors:  B Balbi; D R Moller; M Kirby; K J Holroyd; R G Crystal
Journal:  J Clin Invest       Date:  1990-05       Impact factor: 14.808

2.  Role of monocyte chemoattractant protein-1 (MCP-1) in Th1 (mycobacterial) and Th2 (schistosomal) antigen-induced granuloma formation: relationship to local inflammation, Th cell expression, and IL-12 production.

Authors:  S W Chensue; K S Warmington; J H Ruth; P S Sanghi; P Lincoln; S L Kunkel
Journal:  J Immunol       Date:  1996-11-15       Impact factor: 5.422

3.  Selection of T lymphocytes bearing limited TCR-Vbeta regions in the lung of hypersensitivity pneumonitis and sarcoidosis.

Authors:  L Trentin; R Zambello; M Facco; C Tassinari; R Sancetta; M Siviero; A Cerutti; A Cipriani; G Marcer; M Majori; A Pesci; C Agostini; G Semenzato
Journal:  Am J Respir Crit Care Med       Date:  1997-02       Impact factor: 21.405

4.  T cell receptor repertoire of T lymphocytes recovered from the lung and blood of patients with sarcoidosis.

Authors:  A Bellocq; D Lecossier; C Pierre-Audigier; A Tazi; D Valeyre; A J Hance
Journal:  Am J Respir Crit Care Med       Date:  1994-03       Impact factor: 21.405

5.  Proliferation, macrophage colony-stimulating factor, and macrophage colony-stimulating factor-receptor expression of alveolar macrophages in active sarcoidosis.

Authors:  H Kreipe; H J Radzun; K Heidorn; J Barth; J Kiemle-Kallee; W Petermann; J Gerdes; M R Parwaresch
Journal:  Lab Invest       Date:  1990-06       Impact factor: 5.662

6.  Role of IL-15, IL-2, and their receptors in the development of T cell alveolitis in pulmonary sarcoidosis.

Authors:  C Agostini; L Trentin; M Facco; R Sancetta; A Cerutti; C Tassinari; L Cimarosto; F Adami; A Cipriani; R Zambello; G Semenzato
Journal:  J Immunol       Date:  1996-07-15       Impact factor: 5.422

7.  Spontaneous expression of the interleukin 2 receptor gene and presence of functional interleukin 2 receptors on T lymphocytes in the blood of individuals with active pulmonary sarcoidosis.

Authors:  K Konishi; D R Moller; C Saltini; M Kirby; R G Crystal
Journal:  J Clin Invest       Date:  1988-09       Impact factor: 14.808

8.  Selective activation and accumulation of oligoclonal V beta-specific T cells in active pulmonary sarcoidosis.

Authors:  J D Forman; J T Klein; R F Silver; M C Liu; B M Greenlee; D R Moller
Journal:  J Clin Invest       Date:  1994-10       Impact factor: 14.808

9.  Role of interleukin-2 release by lung T-cells in active pulmonary sarcoidosis.

Authors:  G W Hunninghake; G N Bedell; D C Zavala; M Monick; M Brady
Journal:  Am Rev Respir Dis       Date:  1983-10

10.  Alveolar macrophage kinetics and multinucleated giant cell formation after lung injury.

Authors:  H Prieditis; I Y Adamson
Journal:  J Leukoc Biol       Date:  1996-04       Impact factor: 4.962

View more
  7 in total

1.  Pancreatitis and duodenitis from sarcoidosis: successful therapy with mycophenolate mofetil.

Authors:  Andrew S O'Connor; Farhad Navab; Michael J Germain; Jonathan K Freeman; Jeffrey G Mulhern; Michael H O'Shea; George S Lipkowitz; Robert L Madden; Gregory L Braden
Journal:  Dig Dis Sci       Date:  2003-11       Impact factor: 3.199

Review 2.  Osteopontin: a key cytokine in cell-mediated and granulomatous inflammation.

Authors:  A O'Regan; J S Berman
Journal:  Int J Exp Pathol       Date:  2000-12       Impact factor: 1.925

3.  Neurosarcoidosis. Clinical description of 7 cases with a proposal for a new diagnostic strategy.

Authors:  Sabrina Marangoni; Vincenza Argentiero; Bruno Tavolato
Journal:  J Neurol       Date:  2005-11-14       Impact factor: 4.849

4.  Association of increased rate of condemnation of broiler carcasses due to hepatic abnormalities with immunosuppressive diseases in the broiler chicken industry in Saskatchewan.

Authors:  Keyvan Amini; Tara Zachar; Shelly Popowich; Tennille Knezacek; Bob Goodhope; Philip Willson; Susantha Gomis
Journal:  Can J Vet Res       Date:  2015-10       Impact factor: 1.310

5.  Sarcoidosis-associated hepatitis C virus infection.

Authors:  F Bonnet; P Morlat; J Dubuc; S De Witte; M Bonarek; N Bernard; D Lacoste; J Beylot
Journal:  Dig Dis Sci       Date:  2002-04       Impact factor: 3.199

Review 6.  Targeting CD4(+) T cells for the treatment of sarcoidosis: a promising strategy?

Authors:  Lindsay J Celada; Wonder P Drake
Journal:  Immunotherapy       Date:  2015       Impact factor: 4.196

7.  Pituitary adenoma with tumoral granulomatous reaction.

Authors:  Bernd W Scheithauer; Ana Isabel Silva; John L D Atkinson; Todd B Nippoldt; Timothy J Kaufmann; Kalman Kovacs; Eva Horvath; Ricardo Lloyd
Journal:  Endocr Pathol       Date:  2007       Impact factor: 3.943

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.